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Abstract 
Introduction: Cutaneous melanoma is the 6th most common malignant cancer in the 
USA. Among different subtypes of melanoma, nodular melanoma (NM) accounts about 
14% of all cases but is responsible for more than 40% of melanoma deaths. Early 
diagnosis is the best method to improve melanoma prognosis. Unfortunately, early 
diagnosis of NM is particularly challenging given that patients often lack identifiable risk 
factors such as many moles or freckles. Moreover, early NM may mimic a range of benign 
skin lesions that are not routinely excised or biopsied in every day practice. For this 
reason, specific clinical and skin imaging clues have been proposed to improve early 
detection of NM. 
Areas covered: The review discusses about the noninvasive tools to diagnose thin 
melanoma, particularly NM. 
Expert commentary: Currently dermatologists present a wide opportunity of diagnostic 
tools. Current data suggest that the early diagnosis of NM is a major challenge as the 
majority of early NM are symmetric, roundish and lack specific pattern. Another promising 
strategy is based on recent data suggesting that artificial intelligence based on deep 
convolutional neural networking (CNN) is able to outperform average dermatologist. 
Further research is necessary to validate the performance of this method in the real world 
and in the clinical setting. 
Keywords: nodular melanoma, dermoscopy, reflectance confocal microscopy, 
noninvasive imaging tools, skin cancer, dermato-oncology. 
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1.Introduction 
Cutaneous melanoma (CM) is the 6th most common malignant cancer in the USA. The 
term CM encompasses a heterogeneous subset of malignant melanocytic proliferations 
that differ significantly respect to their epidemiology, morphology, growth dynamics, 
genetics and potential to metastasize. Currently, 3 main groups are distinguished, slow 
growing melanoma (superficial spreading melanoma), fast growing melanoma (nodular 
subtype) and classical lentigo maligna melanoma. Among various subtypes of CM, nodular 
melanoma (NM) accounts for 14% of all CM but is responsible for more than 40% of 
melanoma deaths [1]. This type of melanoma is characterized by a rapid growth rate and 
the estimated invasion rate of NM is about 0.5-mm per months [2]. Regardless of the 
striking differences between these three main groups of melanoma, many still agree with 
the traditional unifying model of melanoma progression, which postulates that all 
melanomas derive from malignant transformed epidermal melanocytes, which initially 
proliferate along the basal layer before acquiring the capability to invade the dermis. 
Because of epidemiological, morphological and genetical differences between NM and 
other subtypes of melanoma, some postulate that NM may origin in the dermis rather than 
in the epidermis and just secondarily will give rise to clinical recognizable features on the 
skin [3, 4]. Data report that about 40-50% of NM will have a tumor thickness of 2+mm at 
time of diagnosis, justifying the hidden intradermal growth that makes clinical visible the 
lesion only at an advanced phase [4, 5]. More than 40% of melanoma deaths are 
attributed to this aggressive form of melanoma [6, 7], this underlines the need for 
improving the early diagnosis of NM. However, this goal is hampered by some challenging 
characteristics of this melanoma subtype. In this manuscript we will provide a practically 
oriented overview of the current literature focusing on strategies to improve early NM 
diagnosis.  
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2.Epidemiology  
Epidemiological data suggest that fast growing NM more commonly affects men, aged 50+ 
years, who lack any of the known melanoma risk factors established for other forms of CM 
such as multiple nevi, freckles or signs of sun-damage [6-8]. Notably, the group of people 
with the highest risk for NM, are also constantly under-represented during skin cancer 
screening programs [9]. On the other hand, screening programs seem to have little impact 
on the prompt diagnosis of early NM, as the majority of tumors develop rapidly de novo on 
previously unaffected skin and are mainly patient detected [10]. According to patients’ 
interviews, the histories of their first taking notice of the tumor are described as “suddenly 
appearing” or “bulging out” of healthy skin [11, 12]. Whether or not, regular skin cancer 
screening examinations will allow for an earlier diagnosis compared to patient self-
detection remains currently questionable; as a matter of fact, we cannot predict when or 
where these melanomas will develop and given their rapid growth (estimated about 0.5-
mm per month [2]), regular skin examinations of at least every 2 months would be required 
for their early detection. Thus, population-based strategies containing images and 
information about the clinical features of NM may represent better strategies to improve 
the knowledge and recognition about this aggressive subtype of CM in a given population.  
3.Clinical features and clues  
Another challenging problem with early NM diagnosis is related to its peculiar clinical 
appearance. Several lines of evidence suggest that the majority of tumors appear as 
clinically symmetric red to pink or gray-blue plaques or nodules with a diameter < 6 mm 
(Fig.1-2) [5, 13, 14].  Accordingly, early NM escape the so-called ABCD rule (asymmetry, 
border irregularity, color variegation and diameter greater than 6 mm) summarizing the key 
features of superficial spreading melanoma [15]. For this reason, alternative rules, named 
the EFG and/or CCC rule have been proposed in the clinical diagnosis of NM [15, 16]. The 
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former EFG summarizes the characteristic features of NM, namely elevation, firmness on 
palpation and continuous growth for more than 1 month [15], while the latter 3C stand for 
color (uniform red to blue), contour (roundish) and change (rapid growth) [16]. Another 
problem related to its clinical features is the fact that it may conceal common benign 
lesions such as hemangiomas, intradermal nevi or seborrheic keratosis [17, 18], which are 
not routinely biopsied as they are usually not included in the differential diagnosis of 
melanoma. As the latter are commonly stable lesions, the history of sudden 
development/evolution and fast growth appear the most important criteria in the diagnosis 
of NM. Nevertheless, a high level of suspicion is required to recognize these early forms of 
NM. For this reason, if after an accurate and careful clinical examination a NM cannot be 
ruled out, immediate excision should be prompted [19].  
4.Non-invasive skin imaging tools   
The introduction of non-invasive diagnostic tools such as dermoscopy and later, 
reflectance confocal microscopy (RCM) improved significantly the clinicians’ diagnostic 
accuracy for melanoma detection [20, 21]. This is because they permit the visualization of 
sub-macroscopic structures invisible for the naked eye [21]. Furthermore, there are more 
recently employed methods in the non-invasive diagnosis of melanoma such as optical 
coherence spectroscopy (OCT) and electrical impedence spectrocopy (EIS), not routinely 
used [22]. However, with the exception of dermoscopy allowing a fast and reliable 
examination of almost all skin lesions, all other methods are limited to clinically selected 
lesions, thus representing second level diagnostic tools for clinically and dermoscopically 
selected equivocal lesions.       
4.1 Dermoscopy of nodular melanoma 
Dermoscopy is a practical and simple non-invasive diagnostic tool that allows having an 
improved diagnosis of skin cancer, particularly pigmented ones. It is based on an optical 
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instrument called dermatoscope that allows to observe sub-macroscopic patterns of skin 
lesions not visible to naked eye. As most dermoscopic features correlate to specific 
underlying histopathologic correlates, it aids clinicians to better predict the 
histopathological diagnosis of a given skin tumor [23]. The dermatoscope is equipped with 
a lens and through a light, able to cross the stratum corneum, allows for the observation of 
cells down to the dermo-epidermal junction and papillary dermis.  
Various dermoscopic criteria such as asymmetry in colors and structures, atypical 
pigmented network, irregular streaks, irregular brown globules, irregular brown structures 
areas and regression features are used to diagnose melanoma, especially superficial 
spreading subtype [24]. Instead, NM often lacks these patterns and represents a 
challenging diagnosis even when examined by dermoscopy. However, there are some 
criteria that should raise the index of suspicion for NM:  
1. Pigmented NMs often lacks the aforementioned features but could be dermoscopically 
recognized by the presence of blue and black colors, defined as a combination of 
structureless blue areas, black dots/ globules, and blotches, involving at least 10% of the 
lesion surface. The so-called blue-black rule has enhanced the discrimination of NMs from 
other benign nodular tumors, such as hemangioma, angiokeratoma, blue nevus or 
seborrheic keratosis [25]. Although blue color is seen in these benign lesions, the 
combination together with black dots and blotches is rarely present in benign skin lesions. 
Blue under dermoscopy has been correlated to the presence of melanin in the deep 
dermis, while black color is associated with both, epidermal melanin or hemoglobin in the 
stratum corneum, but also with dermal aggregates of pigmented melanocytes under an 
attenuated, thinned epidermis. For this latter reason black color may be even predictive for 
a high-risk ulceration [26]. For changing heavily pigmented skin lesions, the so-called BB 
rule represents a highly effective and important clue for the diagnosis of pigmented NM 
(Fig.3) [25]. 
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2. It is well documented that NM often lacks pigmentation (Fig.4) [27]. In case of 
amelanotic or hypomelanotic NM (AHNM) the diagnosis does not rely on pigmented but 
vascular patterns [28]. While true amelanotic melanoma lacks any pigmentation, AHNM is 
characterized by residual pigmentation or light pigmentation [29]. In the latter forms, the 
presence of brown, gray or blue pigment, especially when seen on the base of a pink 
nodule, are helpful criteria to raise the suspect of melanoma. In cases of amelanotic 
melanoma, milky-red areas, short white shiny streaks (only seen under polarized 
dermoscopy) and polymorphous vascular pattern are the only clues for the diagnosis [27, 
28]. Polymorphous vessels are defined as more than one morphological type of vessel; the 
most frequent combination of vessel types seen in melanoma is linear, coiled and dotted. 
Notably, in contrast to basal cell carcinoma or well-differentiated squamous cell carcinoma, 
which are characterized by evident larger size vessels, NM more frequently exhibits micro-
vessels of small diameter and length (personal observation). Milky red globules are 
defined as unfocused large ovoid or polygonal structures of pink-white color, often showing 
a central linear irregular or corkscrew vessel. This latter probably represents neo-
angiogenesis [28]. It has been shown that thin AHNM is more difficult to diagnose than 
thick one, as in thin tumors vessels the vascular polymorphism is less evident [28-30]. 
Short, shiny white streaks (also known as white thick lines, chrysalis or crystalline 
structures) are seen only under polarized dermoscopy, but represent an important criterion 
for the diagnosis, especially when associated with polymorphic vessels or pink areas [31]. 
Although short, shiny white streaks are not very specific for the diagnosis of NM, it is only 
rarely seen in benign skin tumors, thus representing an important management criterion 
[32]  
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The clinical diagnosis of NM remains challenging even if coupled with dermoscopy. For 
this reason, specific management rules have been introduced, combining clinical and 
dermoscopic criteria [33].  
1. Any nodular lesion that cannot be confidently diagnosed as benign lesion requires 
immediate excision. Dermoscopic follow-up of doubtful nodular lesion is strongly 
discouraged, because in the case of NM, it might worsen the prognosis [19]. 
2. Pyogenic granuloma and NM may reveal overlapping clinical and dermoscopic 
criteria that do not allow differentiating between both entities. Therefore, the 
diagnosis of pyogenic granuloma should always be confirmed by histopathology, 
irrespective of the age of the patient. The latter statement is based on the fact that 
atypical spitzoid tumors, often affecting children, are also included in the differential 
diagnosis of pyogenic granuloma. Destructive methods such laser therapy and/or 
liquid nitrogen are strongly discouraged as they destroy tissue without the possibility 
of a histopathological examination [34] 
3. Pink lesions with the suspect of a spitzoid neoplasm should be always excised, 
irrespective of age of the patient [34-7].  
4. Any ulcerated non-pigmented nodule should be excised [19].  
5. Any lesion showing polymorphous vessels should be excised [38].  
6. Pink lesions, for which dermoscopy does not confirm the clinical suspected 
diagnosis, should be dealt with caution [19].  
7. Blue nodules, lacking a convincing subjective history of a stable lesion a/o showing 
dermoscopically blue and black areas, should be excised [25] 
4.2 Reflectance Confocal Microscopy in nodular melanoma 
Reflectance Confocal Microscopy (RCM) is a non-invasive diagnostic tool that allows the 
observation of structures at a quasi-histopathologic resolution. For this reason, RCM is 
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considered by some as virtual biopsy. RCM uses a diode as a monochromatic light that is 
able to penetrate the skin thickness. This light is reflected and generates an image in the 
detector on the base of the different refractive index of the tissue [22].    
Histologically, NMs are characterized by vertical growth without evidence of an associated 
radial growth beyond the width of three rete ridges beyond the invasive component [39].  
RCM has contributed significant improvement in the early diagnosis of NMs. Some authors 
proposed a semi-quantitative algorithm for RCM evaluation of melanocytic lesions. They 
include: two major criteria, presence of non-edged papilla and cytologic atypia; four minor 
criteria, presence of roundish cells in the superficial layers, pagetoid cells widespread 
throughout the lesion, cerebriform clusters and nucleated cells within the dermal papilla 
[40]. NM lacks some confocal features of the superficial spreading melanoma, such as 
epidermal disarrangement and pagetoid spreading. Massive proliferation in the dermis 
causes missing of the typical papillary architecture. Basal layer and upper dermis show 
pleomorphic cells with bright cytoplasm and dark nuclei, whereas amorphous, 
hyporefractive nest called "cerebriform nest" are found in the deep dermis. This latter is a 
relevant criterion for the diagnosis of NM [20]. Other authors correlate dermoscopic BB 
feature with confocal features in NM [21]. Dermoscopic black color is associated with two 
different patterns: large black blotches and irregular black dots/globules. Black blotches 
result from the epidermis being totally filled by upward-migration melanocytes as nests and 
pagetoid cell, whereas black dots/globules correspond to the epidermis having spared 
areas between the upward-migrating nests and pagetoid cells. Black color results not only 
from epidermal melanin or hemoglobin (in case of ulceration), but also from a dense 
dermal proliferation of pigmented melanocytes under a significantly thinned, yet not 
ulcerated epidermis. Accordingly, black color may be even predictive of ulceration before it 
took place [26], which is a known, negative prognostic criterion. The dermoscopic criterion 
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of short shiny white streaks appears to correlate dermal fibrosis or collagen bundles under 
RCM [20, 41].  
Furthermore, RCM has been demonstrated to be an add-on diagnostic tool especially in 
the context of amelanotic/hypopigmented melanocytic tumors, because of the high 
refractive index of melanocytes that produce visible reflections upon the RCM 
examination, allowing for an improved recognition and differentiation between these 
difficult to diagnose lesions. Therefore, combination of dermoscopy and RCM represents a 
valuable method to detect AHNM [42]  
5.Other Non-invasive Methods 
Besides dermoscopy and RCM, which are evidence proven methods for improving the 
melanoma diagnosis, more recent new non-invasive diagnostic tools have been introduced 
to aid the early detection of melanoma. These include optical coherence spectroscopy 
(OCT) and electrical impedence spectrocopy (EIS) [22]. However, these instruments are 
limited to specialized centers and not yet implemented in the daily routine.  
5.1 Optical Coherence Tomography (OCT) 
OCT is a non-invasive diagnostic tool, first developed in ophthalmology, but is now also 
used in dermatology [22, 43] OCT is an interferometric procedure, able to detect the 
intensity of backscattered infrared light from biological tissue by measuring the optical path 
length [43]. Different OCT methods are studied: Frequency Domain OCT (FD-OCT), 
Dynamic OCT (D-OCT), High Definition OCT (HD-OCT). FD-OCT is primarily used in the 
diagnosis of basal cell carcinoma and other non-pigmented skin cancers.  
Although there are some reports on the OCT patterns of melanoma, [43-47] further studies 
are needed to understand the real role of OCT in the early diagnosis of NM. 
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5.2 Electrical Impedence Spectrocopy (EIS)  
Electrical impedence spectroscopy (EIS) is a novel not visual method employed in skin 
cancer diagnosis. This method does not make a diagnosis but suggests based on scores 
whether a lesion should be considered benign or malignant. EIS relieves the current that 
flows between the cells. Tumor cells are characterized by irregular curves due to their 
polymorphism. From these curves, the system calculates a score that reflects the degree 
of abnormality of the lesion. In a pivotal trail [47], EIS has proved to achieve a high 
sensitivity (96.6%) without fully compromising the specificity (34,4%) however, the system 
is limited to flat tumors and therefore further studies are needed for assessing its role in 
the diagnosis of NM [22]. 
6.Expert commentary  
Currently, dermatologists present a wide opportunity of diagnostic tools, that includes the 
aforementioned dermoscopy, RCM, OCT and EIS. Other non-invasive diagnostic tools 
include dermatofluoroscopy, optoacoustic imaging and other diagnostic tools not validated 
for the diagnosis of pigmented lesions, nor for NM. [22] 
Current data suggest that the early diagnosis of NM is a major challenge as the majority of 
early NM are symmetric, roundish and lack specific pattern. Moreover, even if diagnosed 
early, the majority of tumors reached already an invasion thickness of 2-mm, for this 
reason known as fast growing melanoma. As most NMs are patient self-detected, 
population-based interventions should aim to make the population aware about the key 
features of this aggressive melanoma subtype, namely a suddenly appearing and fast 
growing pink or blue nodule.   
 Another promising strategy is based on recent data suggesting that artificial intelligence 
based on deep convolutional neural networking (CNN) is able to outperform average 
dermatologist. CNN is able to classify skin lesions using only pixels and disease labels as 
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inputs. This fast method could be used on mobile device and has the potential to increase 
the decision-making power in clinical practice. Further research is necessary to validate 
the performance of this method in the real world and in the clinical setting [48].  
Other possibility is the use of smartphone application. Currently the list of available apps 
are able to provide educational materials, photographic atlas and skin self-examination 
tutorial. These apps allow the self-surveillance and through digital images they detect 
changing and new moles during their self-examination. Some apps allow risk class 
stratification of the pigmented lesion in high, medium and low risk by using pattern 
recognition software comparing a database of nevi with confirmed melanoma diagnoses. 
The problem is the risk of misclassified lesions, mostly for NM [49]. The use of smartphone 
and internet have introduced teledermatology, a way to transmit medical information to a 
dermatologist for remote evaluation. Medical information includes clinical history, 
macroscopic and dermoscopic photos, if possible [50]. Teledermoscopy is a rapidly 
evolving method that follows a direct patient care model by enabling patient to initiate a 
consultation with a dermatologist. The consultation in teledermoscopy is store-and-
forward: patient's medical information is stored and then reviewed by a medical provider 
[50]. The expected benefits are an accurate risk indication, immediate response of 
dermatologist and finding skin cancer early. Furthermore, teledermoscopy could partially 
resolve the problem of accessing to a specialist. Limitations are the inability to complete 
full-body examination, particularly for genital area of the body and the risk of misdiagnosis.  
[50] Some authors demonstrate that these applications have a sensitivity for melanoma of 
73% and specificity of 83%, whereas dermatologists have sensitivity of 88% and specificity 
of 97%. [51] Other authors demonstrate that smartphone apps have scarce scientific 
evidence, studies are small and have low methodological quality and only one-third of the 
app has assessed diagnostic accuracy [52]. Thus, new apps may come to the market, 
which may significantly aid the diagnosis of early NM. 
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7.Five-year view 
Early NM diagnosis is a problem related to its peculiar clinical appearance and rapid 
growth rate. While regular screening programs are unlikely to detect NM at early stage, 
population-based strategies aiming to increase the knowledge and awareness about risk 
factors and clinical features associated with fast growing NM seem more promising 
attempts to allow for an earlier detection of NM. Particularly the development of artificial 
intelligence in skin cancer detection may play a crucial role in both, population-based 
information and self-detection of aggressive forms of melanoma.   
 
Key issues 
• NM does not follow the classic melanoma growth but presents an early 
invasiveness and causes a high percentage of deaths due to melanoma. 
 
• Its clinical diagnosis is complicated by its unusual clinical appearance, which often 
does not present the classic characters of melanoma and sometimes mimics benign 
lesions 
 
• Classical skin cancer screening campaigns are unlikely to improve early diagnosis 
of NM.  
 
• Future interventions should target on key features such as a rapidly growing blue or 
red nodule on a population-based level in order to increase the self-detection 
 
• Clinical and dermoscopic and RCM features along with specific management rules 
have been introduced in order to correctly miss difficult to diagnose NM.  
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• Further studies on methods using artificial intelligence may contribute to further 
improvements in the diagnosis of early NM.  
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Figure 1: Pigmented NM localized on the dorsum of the foot 
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Figure 2: Hypomelanotic NM localized on the lower limb 
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Figure  3: Dermoscopy of pigmented NM of fig.1: black-blue positive NM without standard melanoma 
criteria 
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Figure 4: Dermoscopy of hypomelanotic NM of fig.2: polymorphous vascular pattern and some brown 
globules (blue arrow) 
